References

  1. Relling, M.V. and W.E. Evans, Pharmacogenomics in the clinic. Nature, 2015. 526: 343-50.
  2. Swen J, Nijenhuis M, de Boer A, Grandia L, Maitland-van der Zee A, Mulder H et al. Pharmacogenetics: From Bench to Byte— An Update of Guidelines. Clin Pharmacol Ther. 2011;89(5):662-673.
  3. Hicks J, Swen J, Thorn C, Sangkuhl K, Kharasch E, Ellingrod V et al. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants. Clin Pharmacol Ther. 2013;93(5):402-408.
  4. Crews K, Gaedigk A, Dunnenberger H, Leeder J, Klein T, Caudle K et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450 2D6 Genotype and Codeine Therapy: 2014 Update. Clin Pharmacol Ther. 2014;95(4):376-382.
  5. Crews K, Gaedigk A, Dunnenberger H, Klein T, Shen D, Callaghan J et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Codeine Therapy in the Context of Cytochrome P450 2D6 (CYP2D6) Genotype. Clin Pharmacol Ther. 2011;91(2):321-326.
  6. Shah R, Smith R. Addressing phenoconversion: the Achilles’ heel of personalized medicine. British Journal of Clinical Pharmacology. 2015;79(2):222-240.
  7. Scott S, Sangkuhl K, Stein C, Hulot J, Mega J, Roden D et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update. Clin Pharmacol Ther. 2013;94(3):317-323.
  8. Hicks J, Bishop J, Sangkuhl K, Müller D, Ji Y, Leckband S et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors. Clinical Pharmacology & Therapeutics. 2015;98(2):127-134.
  9. Schroth, W et al. JAMA 302(13):1429-1436 (2009). Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with Tamoxifen.
  10. Walko, CM and Mcleod, H. Pharmacogenomics 13(6): 691-697 (2012). Use of CYP2D6 genotyping in practice: Tamoxifen dose adjustment.
  11. Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, et al. SLCO1B1 variants and statin-induced myopathy-a genomewide study. N Eng J Med. 2008 Aug 21;359(8):789-99.
  12. Ramsey LB, Johnson SG, Caudle KE, Haidar CE, Voora D, Wilke RA, et al. The Clinical Pharmacogenetics Implementation Consortium Guidelines for SLCO1B1 and Simvastatin-Induced Myopathy: 2014 Update. Clin Pharmacol Ther. Online publication 9 July 2014. doi:10.1038/clpt.2014.125